PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells

Molecular Cancer Therapeutics

Volumn 9, Issue 7, 2010, Pages 1977-1984

  Kim, JinKoo ^a   Guan, Jean ^a   Chang, Insoon ^a   Chen, Xiaohong ^a,b   Han, Demin ^b   Wang, Cun Yu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; PROTEIN NOXA; TRICHOSTATIN A; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; HEAD AND NECK CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; ACETYLATION; ANIMAL; CARCINOMA, SQUAMOUS CELL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; NORTHERN BLOTTING; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CASPASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; HEAD AND NECK NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954618581     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0141     Document Type: Article

References (34)

1. Lemaire F, Millon R, Wasylyk B, et al. Differential expression profiling of head and neck squamous cell carcinoma (HNSCC). Br J Cancer 2003;89:1940-9.
2. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
3. Pisani P, Bray F, Ferlay J, Parkin DM. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Fribley A, Evenchik B, Wang CY, et al. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006;281:31440-7.
5. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stressreactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-704.
6. Fleming JA, Lightcap ES, Sadis S, Thoroddsen V, Bulawa CE, Blackman RK. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. Proc Natl Acad Sci U S A 2002;99:1461-6.
7. Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Can Biol Ther 2006;5:745-8. (Pubitemid 44775127)
8. Wang Q, Mora-Jensen H, Ye Y, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only proteain NOXA in cancer cells. Proc Natl Acad Sci U S A 2009;106:2200-5.
9. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Waes CV. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative Nuclear Factor-κB subunits in head and neck cancer. Clin Cancer Res 2008;14:4175-85.
10. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269:7-17.
11. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009;107:600-8.
12. Bi G, Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 2006;3:285-90.
13. 2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol 2009;218:467-77.
14. Long J, Zhao J, Yan Z, Liu Z, Wang N. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40. Int J Cancer 2009;124:1235-44.
15. Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 2006;25:3885-93.
16. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 2008;25:183-9.
17. Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res 2006;348:1245-53.
18. Zhang QL, Wang L, Zhao WL, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009;23:1507-14.
19. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden R. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009;15:570-7.
20. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Waes CV. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007;6:37-50.
21. Heider U, Rademacher J, Sezer O, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Hematol 2009;82:440-9.
22. Hideshima T, Bradner JE, Anderson KC, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
23. Catley L, Weisberg E, Anderson KC, et al. Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-9.
24. Bazzaro M, Lin Z, Roden R, et al. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008;14:7340-7.
25. Ameri K, Harris AL. Activating transcription factor 4. Int J Biochem Cell Biol 2008;40:14-21.
26. Niknejad N, Morley M, Dimitroulakos J. Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem 2007;282:29748-56.
27. Milani M, Rzymski T, Harris AL, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib. Cancer Res 2009;69:4415-23.
28. Kojima E, Takeuchi A, Isobe K, et al. The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress-elucidation by GADD34-deficient mice. FASEB J 2003;17:1573-5.
29. Ri M, Iida S, Ueda R, et al. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci 2009;100:341-8.
30. Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 2002;8:662-4.
31. Inoue S, Riley J, Gant TW, Dyer MJS, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007;21:1773-82.
32. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008;180:1131-6.
33. Zhang B, West EJ, Lyeth BG, et al. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 2008;1226:181-91.
34. Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009;113:4289-99.